14 FEB 2012 / Product News
Actavis offers Donepezil on first day of patent expiry
Following patent expiry at midnight on 13th February, Actavis has launched Donepezil on day one. The product is available in two forms: tablets and oro-dispersible tablets.
Donepezil is indicated for the treatment of mild to moderately severe Alzheimer’s disease. Actavis is offering both forms of Donepezil in 5mg and 10mg strength in packs of 28 tablets.
Michael Cann, Director Generics said: "We are proud to have launched two products on day one of patent expiry within the last four weeks. Actavis is committed to delivering products on day one and this will continue to be a focus throughout 2012.”
All products are available through major wholesalers or directly from the Actavis Customer Service team on telephone: 0800 731 0370 or fax: 0800 731 0380.